StreetAlpha
13F holdings · Q3 2026

Silverarc Capital Management

Boston, MA · files as Silverarc Capital Management, LLC
Know the moment Silverarc Capital Management filesYou follow Silverarc Capital Management An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Holdings as of Sep 30, 2026Filed Nov 12, 2026Next filing due Feb 15, 2027CIK 1816307

Silverarc Capital Management reported 63 stocks worth $821M in its 13F filing for Q3 2026, filed Nov 12, 2026. Its largest holdings are KOD (8.7%), CELC (7.8%) and COGT (6.1%). Compared with Q2 2026, the fund opened new positions in CLDX, RNAQU and YARW, added to KOD, CELC and COGT, trimmed URGN, ASND and DNTH and sold out of VCYT, GH and TRVI.

Latest filing: what Silverarc Capital Management did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
15 new26 added20 trimmed17 sold outBought about $214M · sold about $231M
New 15
See all 15 →
Added 26
See all 26 →
Trimmed 20
See all 20 →
Sold out 17
See all 17 →

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$821M−8.6% vs last quarter · $854M including options
Stocks held6315 new · 17 sold out
Top 5 weight33.8%spread out
Turnover54%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
KOD
Kodiak Sciences Inc
$71.1M8.7%750K+204K (+37%)8 of 8
2
CELC
Celcuity Inc
$63.9M7.8%803K+302K (+60%)5 of 8
3
COGT
Cogent Biosciences Inc
$50.4M6.1%1.6M+294K (+23%)6 of 8
4
URGN
Urogen Pharma Ltd
$46.7M5.7%1.1M−153K (−12%)8 of 8
5
IMNM
Immunome Inc
$45M5.5%2.1M+76K (+4%)4 of 8
6
GLUE
Monte Rosa Therapeutics Inc
$37.1M4.5%3.1M+2M (+181%)5 of 8
7
SGMT
Sagimet Biosciences Inc
$37M4.5%3.7M+818K (+28%)3 of 8
8
ASND
Ascendis Pharma A/s
$34.7M4.2%152K−54K (−26%)2 of 8
9
RYTM
Rhythm Pharmaceuticals Inc
$33.2M4.0%348K+37K (+12%)8 of 8
10
BIIB
Biogen Inc
$25.5M3.1%113K+65K (+134%)5 of 8
🔒 53 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
VCYT
Veracyte Inc
$18.7M318K
GH
Guardant Health Inc
$15M100K
TRVI
Trevi Therapeutics Inc
$12.6M678K
MANE
Veradermics Inc
$11.7M95K
XENE
Xenon Pharmaceuticals Inc
$11.3M187K

🔒 Free account: see all 17.

Options

valued at the underlying shares
StockTypeValueSharesChange
CLDX
Celldex Therapeutics Inc New
Call$12M371K+370,700
ORIC
Oric Pharmaceuticals Inc
Call$9.5M702K+19,800
GLUE
Monte Rosa Therapeutics Inc
Call$6.3M525K+225,000
ABSI
Absci Corporation
Put$2.7M255K+97,100
FULC
Fulcrum Therapeutics Inc
Call$1.5M392K0

🔒 Free account: see all 7.

Reported value

last 8 quarters
$447MQ4 '24
$479MQ1 '25
$489MQ2 '25
$691MQ3 '25
$691MQ4 '25
$849MQ1 '26
$899MQ2 '26
$821MQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 12, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Silverarc Capital Management 13F FAQ

What does Silverarc Capital Management own?

Silverarc Capital Management reported 63 stocks worth $821M in its 13F filing for Q3 2026, filed Nov 12, 2026. Its largest holdings are KOD (8.7%), CELC (7.8%) and COGT (6.1%). The table above lists every position in the filing (the top 10 without an account).

What did Silverarc Capital Management buy and sell in Q3 2026?

Compared with Q2 2026: 15 new positions, 26 added to, 20 trimmed and 17 sold out. New positions include CLDX, RNAQU and YARW. It sold all of VCYT, GH and TRVI.

When will Silverarc Capital Management file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Silverarc Capital Management's portfolio worth?

The Q3 2026 filing reports $821M in US stocks ($854M including options). That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.